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of High Dose Rate (HDR) Brachytherapy for Curative
Treatment of Carcinoma Cervix
Nasir Ali, Bilal Mazhar Qureshi, Ahmed Nadeem Abbasi, Asim Hafiz, Benazir Mir Khan and Abdul Qadir Jangda
Radiation Oncology Section, Department of Oncology, The Aga Khan University, Karachi, Pakistan
ABSTRACT
To determine the acute vaginal mucosal toxicity and clinical response of cervical cancer after definitive treatment with external
beam radiotherapy (EBRT) and three fractions each of 8 Fray (Gy) high dose rate intracavitary brachytherapy (HDR-BT).
Study Design: Descriptive study.
Place and Duration:  Radiation Oncology Section,  Department of  Oncology,  The Aga Khan University  Hospital,  Karachi,
Pakistan from January 2008 till December 2015.
Methodology: Protocol was formulated for carcinoma cervix to complete treatment in 7 weeks. Patients were treated with
chemotherapy and pelvic EBRT to a total dose of 45 Gy/25 fractions, followed by three intracavitary HDR brachytherapy frac-
tions of 8 Gy each. Vaginal toxicity and local clinical response was assessed at the end of treatment, at 4 and 8 weeks.
Results: A total of 57 patients were treated with HDR brachytherapy and 49 patients were evaluated for assessment of
toxicity and response. According to FIGO staging system, two had stage IB2, one had IIA, thirty-six had IIB, seven had IIIB, one
had IVA disease and two had IVB with para aortic nodes. Concurrent gemcitabine and cisplatin were given to 26 (46%);
whereas, 28 (49%) received concurrent cisplatin alone. Grade III acute vaginal mucosal toxicity was seen in 52 and Grade IV
acute vaginal mucosal toxicity was observed in 08 patients. At completion of treatment, 40 patients had complete clinical
response, at 4 weeks follow-up, complete regression of disease was found in 3 more and at 8 weeks none had clinical residual
disease.
Conclusion: This regimen of HDR brachytherapy treatments is feasible, efficacious, and well-tolerated for carcinoma cervix in a
setup with cost constraints. Long term toxicity and disease control remains to be reported with longer follow-up.
Key Words: Carcinoma cervix, High dose rate brachytherapy, Acute toxicity, Local response, External beam radiation therapy, Intra-
cavitary brachytherapy.
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INTRODUCTION
Cervical  cancer is a disease of developing countries lacking
human  papilloma  virus  screening;  and  ranks  third  most
common malignancy among females in Pakistan.1,2 The stan-
dard treatment for locally advanced cervical cancer is cisplatin
based  concurrent  chemoradiotherapy  and  brachytherapy.3
While brachytherapy is an integral part in the management of
cervical cancer, it is also established that entire treatment must
be completed in a specified time of 7-8 weeks.4
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In a series of 113 women diagnosed with stage IB to IIIB cervical
carcinoma, at a median follow-up of 26 months, time to comple-
tion of treatment more than 56 days was associated with a
higher rate of disease progression within the pelvis 26% versus
9%.5 Though American Brachytherapy Society (ABS) has recom-
mended  fractionation  schedules  of  high  dose  rate
brachytherapy  (HDR-BT)  according  to  stage  of  disease,  still
there is wide variation in prescribed fractionation schedule of
HDR-BT  in  literature.6  At  the  time  of  inception  of  HDR-BT
services at the study centre in late 2007, the authors empirically
formulated a three fractions schedule of brachytherapy with the
intention to complete entire treatment in 7 weeks duration,
used as three fractions HDR brachytherapy of 8 Gy each in these
patients.  It  was  important  to  evaluate  the  grade  of  vaginal
mucosal toxicity and response of local disease at completion of
treatment and on early follow up by clinical examination for this
treatment.
The  aim  of  this  study  was  to  report  acute  vaginal  mucosal
toxicity and clinical response of cervical cancer after definitive
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treatment with external beam radiotherapy (EBRT) and three
fractions  each  of  8  Gray  (Gy)  high  dose  rate  intracavitary
brachytherapy (HDR-BT).
METHODOLOGY
After the inception of HDR-BT services at the Aga Khan Univer-
sity, a road map was developed for the treatment of cervical
cancer patients with the aim to complete the treatment in seven
weeks. It was mandatory for all patients to undergo pelvic exami-
nation  under  general  anesthesia  for  staging  and  biopsy  of
cervical mass and cystoscopy and procto-sigmoidoscopy when-
ever required; systemic staging work up comprised of contrast
enhanced CT scan of chest abdomen and pelvis. Therefore, all
the patients with locally advance cervical cancer were managed,
after  pretreatment  evaluation  with  the  treatment  scheme
mentioned below, from January 2008 till December 2015.
After staging and pre-treatment workup, patients started treat-
ment with external beam radiation therapy (EBRT) and concur-
rent weekly chemotherapy,  preferably on first  day.  Patients
were  evaluated  and  considered  for  smit  sleeve  insertion  in
fourth week of treatment under general anesthesia by gynae-
oncologist. First fraction of brachytherapy was delivered during
fourth or fifth week of treatment before completion of external
beam radiation therapy. Patients did not receive EBRT on the
day of brachytherapy. 
All patients were treated with concurrent chemotherapy and
EBRT and HDR-BT. CT based 3-D conformal EBRT planning was
preferred. The dose of EBRT consisted of 4500 cGy over 25 frac-
tions on 18MV linear accelerator over five weeks. Superior limit
of the anterior and posterior field was kept at L4-5 junction, infe-
rior border was kept 2- 3 cm below the palpable tumor in vagina
or at base of obturator foramen, whatever was inferior. Later-
ally, the field extended 2 cm to the bony margin of pelvis. Lateral
field borders were placed at the 2nd and 3rd sacral space at poste-
rior  margin  and  anterior  border  was  placed  at  the  anterior
cortex of pubic symphesis. Cranio-caudal length of lateral field
was equal to the length of anterio-posterior fields. However, in
patients with para aortic lymphadenopathy superior border of
the fields was placed at top of twelfth thoracic vertebra. Multi
leaf collimators were used to block the normal tissue as much as
possible without compromising the dose to the planning target
volume (PTV).
Concurrent chemotherapy during EBRT was part of treatment
plan. Patients receiving single agent cisplatin got dose of 40
mg/m2 every week. Patients receiving doublet chemotherapy
had cisplatin 40 mg/m2 and gemcitabine 125 mg/m2 on weekly
basis.  This  was  followed  by  adjuvant  two  cycles  of  same
chemotherapy, i.e. cisplatin 50 mg/m2 on day 01, gemcitabine
1000 mg/m2 on day 01 and 08, cycle to be repeated at 3 weeks
interval. One patient had second primary of locally advanced
left breast cancer as well, so she received carboplatin at the
dose of area under the curve (AUC) 5, and paclitaxel 80 mg/m2
weekly during pelvic EBRT, and after completion of radiation
therapy she received four cycles of Adriamycin and cyclophos-
phamide chemotherapy then subjected to left modified radical
mastectomy followed by left chest wall and regional nodal radia-
tion therapy.
HDR brachytherapy was delivered at  8 Gy per fraction with
weekly interval, first fraction of brachytherapy was delivered
during last week of EBRT and, EBRT fraction was not delivered
on the day of HDR-BT as shown in Table I of road map to cervical
cancer treatment. Irredium-192 HDR treatment was used with
GammaMed machine. The selection of applicator was done by
the  radiation  oncologist  on  vaginal  examination  before
brachytherapy procedure between either Fletcher Suit Delclos
Tandem and Ovoid applicators or Tandem and Ring applicators.
HDR-BT dose was prescribed at right and left point A. Insertion of
applicators  were  done  under  general  anesthesia.  Careful
vaginal packing was done to displace the bladder and rectum
away from the applicators (Figures 1 and 2). HDR treatment
planning was performed on Abacus treatment planning in first
half  of the total  duration and on Eclipse planning system in
second half of study period.
Acute vaginal mucosa toxicity was recorded at conclusion of
HDR brachytherapy, and four and eight weeks after completion
of treatment according to the Common Terminology Criteria for
Adverse  Events  (CTCAE)  Version  4.0.7  Toxicity  assessment
results were recorded in patient’s confidential records.
Tumor bi-dimensional measurements were recorded at start of
treatment and response was done by bi-dimensional measure-
ment of cervical mass by the same physicians after completion
of treatment. During concurrent chemoradiotherapy complete
blood  count  and  serum  creatinine  were  checked  in  all  the
patients at weekly interval.
After completion of treatment, patients were followed every
two months in first year, three months in second and 6 monthly
in the subsequent years. Follow up was done by physical exami-
nation, cervical cytology, and when required by pelvic MRI or CT
scans.  All  patients  were  instructed  to  use  vaginal  dilator  to
prevent vaginal adhesions and stenosis.
Patient who received EBRT in an outside centre (five patients)
were censored form this analysis of toxicity assessment. Statis-
tical Analysis was done using IBM Statistics 20.
RESULTS
A total of 57 patients received brachytherapy at this Institute
from  January  2008  till  December  2015.  The  mean  age  of
patients was 53 ±12.5 years ranging from 24-83. The mean
duration of overall treatment time was 56 days. This group had
squamous cell carcinoma in 51 (90%) and adenocarcinoma in 5
(9%) of patients. Only one patient was diagnosed to have poorly
differentiated small cell carcinoma. All the patients were staged
according to FIGO staging system, 40 (70%) patients had FIGO
Stage IIb disease. Three patients had FIGO stage IVb disease by
virtue  of  paraortic  lymphadenopathy,  without  any  distant
metastasis.
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Table I: Road map to cervical cancer definitive treatment.
Weeks Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 CRT RT RT RT RT Off Off
2 CRT RT RT RT RT Off Off
3 CRT RT RT RT RT Off Off
4 CRT RT RT RT Smit’s sleeve insertion Off Off
5 CRT RT RT RT HDR 1 Off Off
6 CRT RT Off Off HDR 2 Off Off
7 Off Off Off Off HDR 3 Off Off
CRT: Chemoradiation therapy; RT: Radiation therapy; HDR: High dose rate.
Figure 1: Anterior simulation X-Ray (inverted) image after insertion
of intracavitary applicators including a tandem and two ovoids. Blue
colour depicts 50% isodose coverage and red indicates 100% (8Gy)
coverage. Central green line denotes the Irridium-192 source step-
ping position in tandem and the two lateral green lines denote the
source stepping position in ovoids. Point A on right (Rt A) and left (Lt
A), bladder and rectal points are marked on this simulation X-Ray
image.
Out of 57 patients, 50 (88%) received external beam radia-
tion therapy in this study. Conventional two-dimensional (2-
D) techniques four-field box was used in five (9%) patients.
Three-dimensional  conformal  planning  was  used  for  45
(79%) of the patients using Varian eclipse treatment plan-
ning system.  Seven (12%) patients were referred to this
facility only for brachytherapy and are included in this anal-
ysis. Concurrent weekly chemotherapy was given to 55 of 57
patients. Cisplatin was given to 28 (49%) patients and combi-
nation of concurrent gemcitabine and cisplatin was given to
26  (46%)  patients.  Two  patients  were  not  given
chemotherapy  because  of  advance  age  and poor  perfor-
mance status. Tandem and Ovoid Fletcher-Suit Delclos-style
Applicator  Set  was  used  for  brachytherapy  in  48  (84%)
patients and Ring Applicator was used in 9 (16%) of patients.
At  the  end  of  treatment,  vaginal  mucosal  toxicity  was
recorded for all of the patients. Grade II vaginal mucositis
was seen in 11 (19%) patients. Grade III mucositis was most
common, seen in 42 (73%).  Only four (7%) patients had
grade IV vaginal mucositis at the end of treatment.
Figure 2: Lateral simulation X-Ray (inverted) image after insertion of
intracavitary applicators including a tandem and two ovoids (overlap-
ping. Blue colour depicts 50% isodose coverage and red indicates
100% (8Gy) coverage. The longer green line denotes the Irridium-192
source stepping position in tandem and the two inferior green lines
denote the source stepping position in ovoids. Point A on right (Rt A)
and left (Lt A), bladder and rectal points are marked on this simula-
tion X-Ray image. Contrast can be seen in rectum.
All patients were evaluated in clinic four weeks after the last
brachytherapy. Eighteen (32%) patients were observed to
have  grade  I  vaginal  mucositis,  grade  II  mucositis  was
present in 37 (65%) and only two (3.5%) patients had grade
III vaginal mucositis. Eight weeks after completion of treat-
ment none of the patients had significant vaginal toxicity.
DICSUSSION
Due  to  lack  of  vaccination,  screening  and  awareness,
females with cervical cancer present with locally advanced
disease in Pakistan.8,9 In a case series from Pakistan, Hashmi
et al. has reported 66% of their patients belonging to stage
IIb,  which  is  similar  to  this  study’s  experience  of  70%.10
Brachytherapy is an integral component in the management
of locally advanced cervical cancer as part of definitive treat-
ment  with  chemo-radiation.3  Traditionally,  low  dose  rate
brachytherapy regimens have been used. However, in more
and more facilities LDR is being replaced by HDR units on
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account of less cost of treatment, less potential complica-
tions, equivalent control and survival rates in favor of HDR
brachytherapy regimens.11-15 Till to date, there is wide varia-
tion in the dose schedule of HDR treatment.16 Optimum dose
schedule  has  not  yet  been  defined,  and  American
Brachytherapy  Society  authors  carefully  stated  that
proposed  recommendations  have  not  tested  clinically.4
The clinicians opted three fractions of HDR brachytherapy of
8 Gy each. The aim was to reduce the cost of treatment and
timely  completion of  chemoradiation therapy,  but  at  the
same time vaginal mucosa toxicity was a concern. There-
fore,  vaginal  mucosal  toxicity  was  graded  according  to
CTCAE  system  and  recorded  at  completion  of  HDR
brachytherapy, at 4 weeks and at eight weeks follow up. In
a  prospective  phase  III  trial  single  agent  cisplatin  was
compared with doublet of cisplatin and gemcitabine and all
patients received a total dose of 5040 cGy EBRT plus LDR
brachytherapy.12 It showed increased systemic toxicity using
doublet chemotherapy regimen. Systemic toxicity in these
patients was not higher that reported in that trial because
we used 4500 cGy over  25 fractions  of  EBRT plus  HDR
brachytherapy in the two arms of chemotherapy regimens.
Since 2007, the dose fractionation has been three fractions
of 8 Gy each at point A. Vaginal grade III mucosal toxicity
was seen in equal proportion in both the chemotherapy regi-
mens used (weekly concurrent cisplatin chemotherapy 40
mg/m2 in 25 patients or cisplatin 40 mg/m2 and gemcitabine
125 mg/m2 in other 25 patients), only in one patient from
Kenya  who  received  concurrent  cisplatin  chemotherapy
alone, had iatrogenic longitudinal tear in vaginal mucosa in
first fraction of HDR treatment, so she was not given subse-
quent two fractions of HDR and given boost of 14 Gy with
EBRT. Hashmi et al has reported complete response in 54%
and  partial  response  in  38%  patients  with  concurrent
cisplatin  chemotherapy  with  only  43%  patients  having
vaginal mucositis.16  However, the timing of recording the
acute toxicity has not been elaborated. In the current study
the toxicity has been reported at three different intervals.
Rectal and bladder point doses according to the ICRU calcu-
lation points at level of external os were kept less than 60%
of dose at point A.13 After two or three fractions, toxicity has
been reported similar to patients in the present study. In a
report by Petereit et al., authors were unable to identify a
total threshold dose or the number of fractions used that
could be taken as a factor contributing to the tissue compli-
cations.14
Total duration of treatment is reported by several authors to
be of clinical significance in patients treated by chemoradia-
tion therapy.17-22  Scheduling of HDR implant also carried a
prognostic  significance  for  local  control  in  patients  with
locally  advanced  disease.  Whenever  patient’s  anatomy
allows brachytherapy should be instituted in third week of
EBRT.23
In the current study majority of the patients presented with
advanced  disease,  most  patients  being  stage  IIB,  so
brachytherapy was instituted in last week of EBRT schedule
allowing for the tumor to shrink and to achieve a good
applicator  geometry.  Only  10  patients  were  able  to
complete the entire treatment in less than 50 days, 25
patients were able to complete in 50-60 days, and 15 took
more than 60 days to complete treatment. The patients
who could not complete treatment in 50 days had delays
due  to  hematologic  toxicity  related  to  chemotherapy,
leading  to  interruptions  in  treatment  or  missed
chemotherapy  cycles.
Response of cervical mass and toxicity was evaluated at
end  of  treatment,  at  4  and  8  weeks.  Though  patients
receiving doublet chemotherapy regimen had slightly more
pronounced vaginal mucosal reactions, there was a trend
of  improvement  of  these  effects  at  four  week  and  eight
week  follow  up.
It is well known that cervical cancer is a one of the leading
problems  for  lower  socio-economic  strata,  which  are
already  resource-limited.24,25  This  treatment  strategy
provides  a  cost-effective  approach.  The  strategy  can  be
adapted  by  radiation  facilities  designed  to  offer  this  cura-
tive  treatment  to  large  population.  It  is  effective  in  this
center as the patients are coming from far flung areas and
mostly have to pay on their own.6
CONCLUSION
This  series  suggests  that  three  fractions  of  HDR
brachytherapy  applications  are  well  tolerated  by  these
patients and toxicity is manageable. Although ABS guide-
lines has suggested to use 4-6 fractions to keep toxicity
less,  it  is  being  proposed  that  increasing  the  fractions
beyond 3 may prolong the treatment duration leading to
compromised outcome. Also using three fractions is cost-
effective in resource-limited setting, because patients come
from remote areas for treatment and have to pay on their
own. Long term disease control and toxicity remains to be
seen in this series of patients and will be reported after a
longer follow-up.
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